Advertisement

Topics

Onxeo: Full-year 2016 Results and Outlook for 2017

12:49 EST 7 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Reinforcement of Onxeo’s strategic positioning in the development of innovative oncology treatments Acquisition of DNA Therapeutics and the AsiDNATM product, a first-in-class candidate in the new area of pr...

Other Sources for this Article

Onxeo
Valerie Leroy, Investor Relations
investors@onxeo.com
+33 1 45 58 76 00
or
Media Relations
Caroline Carmagnol / Simon Derbanne -Alize RP
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 6 38 16 26 41
or
Investor Relations / Strategic Communications
Dušan Orešanský / Emmanuel Huynh – NewCap
onxeo@newcap.eu
+33 1 44 71 94 92
or
Investor & Media Relations US
Kirsten Thomas / Lee Roth – The Ruth Group
kthomas@theruthgroup.com / lroth@theruthgroup.com
+1 508 280 6592 / +1 646 536 7012

NEXT ARTICLE

More From BioPortfolio on "Onxeo: Full-year 2016 Results and Outlook for 2017"

Advertisement
Quick Search
Advertisement
Advertisement